There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis

There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis.

“We identified 16 randomized placebo-controlled trials investigating cannabinoids as symptomatic treatment in multiple sclerosis (MS).

There is evidence that nabiximols (THC/CBD) oromucosal spray may reduce subjective symptoms of spasticity and that dronabinol (THC) is effective against neuropathic pain in patients with MS…”

http://www.ncbi.nlm.nih.gov/pubmed/25350886  (PubMed)


This Research and Resources page is sponsored by the Ohio Rights Group Education Fund.
Please support our charitable and educational work by making a generous tax deductible donation.